133 related articles for article (PubMed ID: 23177093)
1. Clinical efficacy of intravenous glucocorticoid treatment in Graves' ophtalmopathy.
Alhambra Expósito MR; Gálvez Moreno MÁ; Moreno Moreno P; Prior Sánchez I; Muñoz Jiménez C; Benito López P
Endocrinol Nutr; 2013 Jan; 60(1):10-4. PubMed ID: 23177093
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
3. The influence of radioiodine therapy on ocular changes and their relation to urine cotinine level in patients with Graves' Ophthalmopathy.
Czarnywojtek A; Zgorzalewicz-Stachowiak M; Budny B; Wasko R; Florek E; Szczepanek E; Komar-Rychlicka K; Waligorska-Stachura J; Kurdybacha P; Miechowicz I; Ruchala M
Neuro Endocrinol Lett; 2013; 34(3):241-8. PubMed ID: 23685424
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
5. Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves' ophthalmopathy.
Ueda-Sakane Y; Kanamoto N; Fushimi Y; Tanaka-Mizuno S; Yasuno S; Miura M; Sone M; Yasoda A; Okada T; Togashi K; Nakao K; Inagaki N
Endocr J; 2016 Aug; 63(8):703-14. PubMed ID: 27263854
[TBL] [Abstract][Full Text] [Related]
6. Smoking was associated with poor response to intravenous steroids therapy in Graves' ophthalmopathy.
Xing L; Ye L; Zhu W; Shen L; Huang F; Jiao Q; Zhou X; Wang S; Wang W; Ning G
Br J Ophthalmol; 2015 Dec; 99(12):1686-91. PubMed ID: 26061160
[TBL] [Abstract][Full Text] [Related]
7. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor.
Vannucchi G; Covelli D; Campi I; Origo D; Currò N; Cirello V; Dazzi D; Beck-Peccoz P; Salvi M
Eur J Endocrinol; 2014 Jan; 170(1):55-61. PubMed ID: 24128430
[TBL] [Abstract][Full Text] [Related]
8. A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves' ophthalmopathy.
Zhu W; Ye L; Shen L; Jiao Q; Huang F; Han R; Zhang X; Wang S; Wang W; Ning G
J Clin Endocrinol Metab; 2014 Jun; 99(6):1999-2007. PubMed ID: 24606088
[TBL] [Abstract][Full Text] [Related]
9. Treatment of mild, moderate-to-severe and very severe Graves' orbitopathy.
Marcocci C; Marinò M
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):325-37. PubMed ID: 22632369
[TBL] [Abstract][Full Text] [Related]
10. [Short-term efficacies of intravenous glucocorticoid therapy for moderate-to-severe Graves' ophthalmopathy].
Guo L; Yang G; Gu W; Jin N; Chen K; Du J; Wang X; Ouyang J; Dou J; Ba J; Lü Z; Mu Y
Zhonghua Yi Xue Za Zhi; 2015 May; 95(20):1572-5. PubMed ID: 26463604
[TBL] [Abstract][Full Text] [Related]
11. Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients.
Ahn HY; Lee JK
J Korean Med Sci; 2020 Jun; 35(23):e177. PubMed ID: 32537950
[TBL] [Abstract][Full Text] [Related]
12. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity.
Zang S; Ponto KA; Kahaly GJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):320-32. PubMed ID: 21239515
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
[TBL] [Abstract][Full Text] [Related]
16. [Steroid therapy for Graves' ophthalmopathy].
Hiromatsu Y
Nihon Rinsho; 2006 Dec; 64(12):2279-85. PubMed ID: 17154092
[TBL] [Abstract][Full Text] [Related]
17. The application of temperature measurement of the eyes by digital infrared thermal imaging as a prognostic factor of methylprednisolone pulse therapy for Graves' ophthalmopathy.
Shih SR; Li HY; Hsiao YL; Chang TC
Acta Ophthalmol; 2010 Aug; 88(5):e154-9. PubMed ID: 20553230
[TBL] [Abstract][Full Text] [Related]
18. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy.
Kahaly GJ; Pitz S; Hommel G; Dittmar M
J Clin Endocrinol Metab; 2005 Sep; 90(9):5234-40. PubMed ID: 15998777
[TBL] [Abstract][Full Text] [Related]
19. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.
Ye X; Zhao H; Liu J; Lu B; Shao J; Wang J
Eur J Endocrinol; 2021 Feb; 184(2):277-287. PubMed ID: 33539318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
